Captrust Financial Advisors Reduces Stake in Exact Sciences Co. (NASDAQ:EXAS)

Captrust Financial Advisors lessened its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 27.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,880 shares of the medical research company’s stock after selling 2,553 shares during the period. Captrust Financial Advisors’ holdings in Exact Sciences were worth $387,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of EXAS. Thompson Investment Management Inc. boosted its holdings in Exact Sciences by 17.8% in the 4th quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company’s stock valued at $13,585,000 after purchasing an additional 36,505 shares during the last quarter. Jones Financial Companies Lllp grew its position in Exact Sciences by 32.2% in the fourth quarter. Jones Financial Companies Lllp now owns 9,508 shares of the medical research company’s stock worth $534,000 after acquiring an additional 2,315 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Exact Sciences during the fourth quarter worth $478,000. Sanctuary Advisors LLC raised its position in Exact Sciences by 2.0% in the fourth quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company’s stock valued at $763,000 after purchasing an additional 269 shares during the period. Finally, Slow Capital Inc. lifted its stake in shares of Exact Sciences by 7.0% in the 4th quarter. Slow Capital Inc. now owns 82,001 shares of the medical research company’s stock valued at $4,608,000 after purchasing an additional 5,346 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Trading Up 0.9%

Shares of NASDAQ:EXAS opened at $56.94 on Tuesday. Exact Sciences Co. has a 52 week low of $39.97 and a 52 week high of $72.83. The company’s 50 day moving average is $46.58 and its two-hundred day moving average is $51.99. The company has a market cap of $10.74 billion, a PE ratio of -10.22 and a beta of 0.92. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.16. The firm had revenue of $706.79 million for the quarter, compared to analyst estimates of $688.58 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. Exact Sciences’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.60) earnings per share. Equities analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on EXAS. Evercore ISI boosted their price objective on shares of Exact Sciences from $60.00 to $66.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. Piper Sandler reduced their price target on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Barclays increased their price objective on shares of Exact Sciences from $55.00 to $75.00 and gave the stock an “overweight” rating in a research report on Friday, May 2nd. William Blair reissued an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 20th. Finally, Guggenheim restated a “buy” rating and set a $60.00 price target on shares of Exact Sciences in a research note on Friday, April 11th. Two investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Exact Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $70.90.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.